Compare SPDR Gold Trust (GLD) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SPDR Gold Trust vs Viatris Inc — how do they compare? SPDR Gold Trust trades at $384.17 (market cap $139.66B), while Viatris Inc trades at $17.52 (market cap $20.03B). The key difference: SPDR Gold Trust is far larger — about 7× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold SPDR Gold Trust for 74 Days and Viatris Inc for 57 Days on average.
| GLD | VTRS | |
|---|---|---|
Market Cap | $139.66B | $20.03B |
Volume | 9,544,773 | 14,109,977 |
52-Week High | $495.90 | $18.27 |
52-Week Low | $362.32 | $9.74 |
Typical Hold Time | 74 Days | 57 Days |
Sector | — | Health |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLD, the SPDR Gold Trust ETF, is trading at $384.45 with a 2.28% daily gain, though technical indicators signal bearish momentum with 17 sell signals versus 2 buy signals. The ETF faces pressure from rising Treasury yields and a strong U.S. dollar, as highlighted in recent financial news. Key support levels are at $373-$377, while resistance sits at $380-$384. Recent market sentiment remains cautious amid Federal Reserve policy uncertainty and inflation concerns.
The outlook for GLD is mixed, with near-term headwinds from monetary policy and currency strength potentially limiting upside. However, gold's role as a hedge against inflation and global debt concerns offers long-term diversification benefits. Risks include further rate hikes and dollar appreciation, but tactical buying opportunities may emerge if support levels hold.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
